In last trading session, KalVista Pharmaceuticals Inc (NASDAQ:KALV) saw 0.45 million shares changing hands with its beta currently measuring 0.81. Company’s recent per share price level of $10.03 trading at -$0.61 or -5.73% at ring of the bell on the day assigns it a market valuation of $495.66M. That closing price of KALV’s stock is at a discount of -54.54% from its 52-week high price of $15.50 and is indicating a premium of 27.22% from its 52-week low price of $7.30.
For KalVista Pharmaceuticals Inc (KALV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.87 in the current quarter.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
Upright in the red during last session for losing -5.73%, in the last five days KALV remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $10.03 price level, adding 8.82% to its value on the day. KalVista Pharmaceuticals Inc’s shares saw a change of 18.42% in year-to-date performance and have moved 5.25% in past 5-day. KalVista Pharmaceuticals Inc (NASDAQ:KALV) showed a performance of 17.17% in past 30-days.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 49.85% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -99.4% in reaching the projected high whereas dropping to the targeted low would mean a loss of -99.4% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -4.83% while estimates for its earnings growth in next 5 years are of 29.77%.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
VR ADVISER, LLC is the top institutional holder at KALV for having 6.25 million shares of worth $73.62 million. And as of 2024-06-30, it was holding 13.5179 of the company’s outstanding shares.
The second largest institutional holder is TANG CAPITAL MANAGEMENT LLC, which was holding about 4.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1252 of outstanding shares, having a total worth of $49.7 million.
On the other hand, Smallcap World Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.37 shares of worth $33.84 million or 6.83% of the total outstanding shares. The later fund manager was in possession of 1.2 shares on Sep 30, 2024 , making its stake of worth around $12.03 million in the company or a holder of 2.43% of company’s stock.
